Dr Edwin Wagena
CEO
“My goal is to help create an empowering, open and inclusive culture, where people feel connected and where everyone can be at their best to make a difference in developing new medicines that will reach patients.”
Edwin was introduced to Sutura’s exciting technology platform in 2020. Together with Liesbeth de Jong, he initially supported the founders of the Company by preparing a drug development plan for Sutura’s first product. Edwin joined the team full-time in April 2021 and took over responsibilities as CEO in November 2021.
Since 2008, Edwin has specialised in the translation as well as commercial development of innovative therapies, including advanced therapy medicinal products (ATMPs), and orphan drugs. Prior to joining Sutura, Edwin was Chief Development Officer for Kiadis, COO of Ixaka (formerly known as Rexgenero), and CEO of Atelerix. Edwin is trained as a clinical epidemiologist and holds a PhD in Medicine from Maastricht University in The Netherlands.
Edwin firmly believes in the importance of personal connection and teams in bringing these promising new medicines to patients.